Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

PTC Completes Rolling NDA Submission to FDA and Submits Phase 3 ACT DMD Clinical Trial Results to EMA for Translarna™ (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J.Jan. 8, 2016 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the completion of its rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).  PTC has also fulfilled the principal requirement of the European Medicines Agency (EMA) in connection with its approval of Translarna in August 2014 by submitting the results of its Phase 3 ACT DMD clinical trial to the agency. Click here for full article.

News Archive